Casgevy Uptake
CRISPR Therapeutics is witnessing substantial uptake of its gene therapy, Casgevy, aimed at treating sickle cell disease and transfusion-dependent beta thalassemia. This innovative therapy generated impressive revenues, amounting to $54 million in the last quarter and a remarkable $116 million overall for the year.
Patient Treatment Growth
In 2025 alone, 64 patients received infusions, with 30 of those occurring just in the fourth quarter. As the year progressed, a total of 147 patients initiated treatment through the first cell collection, marking a significant increase in patient initiations that nearly tripled compared to previous years, showing strong momentum heading into 2026.
Analyst Confidence
William Blair highlighted the promising data, noting, "The increase to 147 first cell collections strengthens confidence that higher initiation volumes will translate into materially greater revenue in 2026." This sentiment captures the positive outlook on CRISPR's financial performance as patient adoption continues to grow.
Pipeline Advancement
Beyond its hematology offerings, CRISPR is making strides in advancing its in vivo liver editing programs. The company is currently conducting Phase 1b trials for its CTX310 candidate, which targets lipid disorders, while further progress is being made with CTX321, a next-generation program focused on Lp(a), which is entering enabling studies. Updates on this initiative are anticipated in the second half of 2026.
Cardiovascular Focus
Analyst Sami Corwin expressed optimism regarding the company’s in vivo cardiovascular gene editing programs, seeing them as significant value drivers. This reflects the increasing excitement surrounding CRISPR's research capabilities in addressing various medical challenges.
CTX611 Developments
Another noteworthy candidate in their pipeline is CTX611, an siRNA-based treatment developed in partnership with Sirius Therapeutics. Currently in Phase 2 trials for patients undergoing knee replacement surgery, this candidate may also have broader applications in treating thromboembolic diseases, showcasing the versatility of CRISPR’s research efforts.
Financial Overview
As CRISPR Therapeutics concluded 2025, they reported having $1.98 billion in cash and marketable securities. Meanwhile, research and development expenses increased to $83.5 million during the fourth quarter, while net losses widened significantly to $130.6 million from $37.3 million a year prior. These figures indicate a robust investment in future breakthroughs despite the rising costs.
CRSP Price Action
At the time of publication, shares of CRISPR Therapeutics experienced an uptick of 8.81%, trading at $53.24. This price action reflects investor confidence in the company’s ongoing developments and potential for growth in the gene therapy market.
Frequently Asked Questions
What is Casgevy?
Casgevy is a gene-editing therapy developed by CRISPR Therapeutics to treat sickle cell disease and transfusion-dependent beta thalassemia.
How much revenue did Casgevy generate?
Casgevy generated $54 million in the fourth quarter and $116 million for the entire year.
What advancements are being made in CRISPR's pipeline?
CRISPR is advancing its in vivo liver editing programs, including CTX310 for lipid disorders and CTX321 for Lp(a).
What are the financial results for CRISPR in 2025?
CRISPR reported $1.98 billion in cash and securities, with R&D expenses rising to $83.5 million and net losses widening to $130.6 million.
How did CRSP shares perform recently?
CRSP shares increased by 8.81% to a trading price of $53.24, indicating a positive market reaction to their advancements.
